Tegacorat

Tegacorat
Clinical data
Other names	GRM-01; GRT-6019
Identifiers
	IUPAC name 6,7-difluoro-8-(6-fluoro-1-methylsulfonylindol-4-yl)-1,4,4,9-tetramethyl-5H-[1,2,4]triazolo[4,3-a]quinoxaline;
CAS Number	2409551-99-9;
PubChem CID	153315807;
ChemSpider	133321735;
UNII	X4A75C2AX8;
Chemical and physical data
Formula	C22H20F3N5O2S
Molar mass	475.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=C(C2=C1N3C(=NN=C3C(N2)(C)C)C)F)F)C4=C5C=CN(C5=CC(=C4)F)S(=O)(=O)C;
	InChI InChI=InChI=1S/C22H20F3N5O2S/c1-10-16(14-8-12(23)9-15-13(14)6-7-29(15)33(5,31)32)17(24)18(25)19-20(10)30-11(2)27-28-21(30)22(3,4)26-19/h6-9,26H,1-5H3; Key:NHPKTDVPWCXNGJ-UHFFFAOYSA-N;

tegacorat is an investigational new drug that is being evaluated by Grunenthal GmbH for the treatment of Duchenne muscular dystrophy.^[1] It is a non-steroidal selective glucocorticoid receptor modulator.^[1]^[2]^[3]

References

1 2 "Tegacorat - Grunenthal GmbH". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Jakob F, Hennen S, Gautrois M, Khalil F, Lockhart A (2025). "Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolism". Frontiers in Pharmacology. 16 1542351. doi:10.3389/fphar.2025.1542351. PMC 11920646. PMID 40110125.
↑ Buttgereit F, Edwards CJ (May 2026). "Novel glucocorticoids: current status and challenges". Rheumatology. 65 (5) keag181. Oxford, England. doi:10.1093/rheumatology/keag181. PMID 41967122.